Best GLP-1 for Weight Loss in 2026

Tirzepatide (Zepbound/Mounjaro) is a dual GLP-1/GIP receptor agonist — the first in its class. By activating both incretin receptors, it produces greater weight loss than GLP-1-only drugs. The SURMOUNT trials showed average weight loss of 20-22% at the 15mg dose, with some participants losing over 25%.

The dual agonism also appears to improve insulin sensitivity more effectively than GLP-1 alone, making tirzepatide particularly promising for patients with type 2 diabetes and obesity.

Semaglutide (Wegovy) set the benchmark for GLP-1 weight loss at 15-17% average reduction (STEP trials). It has the most comprehensive data package including cardiovascular outcome data from the SELECT trial showing a 20% reduction in major cardiovascular events.

Semaglutide's track record, extensive safety data, and proven cardiovascular benefits make it the most evidence-backed option currently available.

Liraglutide (Saxenda) was the first GLP-1 agonist approved for weight management. At 3.0mg daily, it produces 5-8% weight loss — effective but significantly less than newer options. The daily injection requirement is also less convenient than weekly alternatives.

Liraglutide may still be appropriate for patients who don't tolerate semaglutide or tirzepatide, or in markets where newer agents aren't yet available.

All GLP-1 agonists share similar GI side effects: nausea, vomiting, diarrhea, and constipation. These are typically worst during dose titration and improve over time.

Tirzepatide may have slightly higher rates of GI effects at max dose due to dual receptor activation. Semaglutide has the most extensive long-term safety data. Liraglutide tends to have milder GI effects but requires daily dosing. All three carry a class warning regarding thyroid C-cell tumors (observed in rodents).

1. Tirzepatide — Best overall weight loss efficacy (20-22%). The dual agonist approach is a meaningful advance.

2. Semaglutide — Best evidence base including cardiovascular outcomes. The proven standard with slightly less weight loss.

3. Liraglutide — First-generation option with moderate efficacy. Still useful but outclassed by newer agents.

Always work with a healthcare provider to determine the best option based on your individual health profile.

Ascension Peptides carries research-grade semaglutide and tirzepatide with third-party purity verification. For investigational research only — these are not substitutes for FDA-approved medications.